ResearcherGilead Sciences (United States)No recent work listed

Nishanthan Rajakumaraswamy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0226-0637; OpenAlex author ID A5012099104. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper

Papers 1

A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinom… Last author DOI 10.1634/theoncologist.2020-0321 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

John J. Nemunaitis · 1 shared paper, 2020 · strength 0.13
- Paper A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Me… DOI 10.1634/theoncologist.2020-0321 ↗
Michael Jon Pishvaian · 1 shared paper, 2020 · strength 0.13
- Paper A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Me… DOI 10.1634/theoncologist.2020-0321 ↗
Erkut Hasan Borazanci · 1 shared paper, 2020 · strength 0.13
- Paper A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Me… DOI 10.1634/theoncologist.2020-0321 ↗
Colin D. Weekes · 1 shared paper, 2020 · strength 0.13
- Paper A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Me… DOI 10.1634/theoncologist.2020-0321 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.